2021
DOI: 10.1093/infdis/jiab310
|View full text |Cite
|
Sign up to set email alerts
|

Overview of the United States’ Immunization Program

Abstract: This manuscript describes the history, background, and current structure of the United States Immunization Program, founded upon public- and private-sector partnerships that include federal agencies, state and local health departments, tribal nations and organizations, healthcare providers, vaccine manufacturers, pharmacies, and a multitude of additional stakeholders. The Centers for Disease Control and Prevention sets the U.S. adult and childhood immunization schedules based on recommendations from the Adviso… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(10 citation statements)
references
References 5 publications
0
10
0
Order By: Relevance
“…3 Children might play an important role in the transmission of COVID-19, highlighting the importance of child vaccinations in the effort to reduce COVID-19 community transmission and hospitalization rates. 4 The U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children ages [5][6][7][8][9][10][11] years in the United States on October 29, 2021, which was endorsed on November 2, 2021, by the Centers for Disease Control and Prevention (CDC) based on recommendations from the Advisory Committee on Immunization Practices. 5 Administrative data reported to CDC showed that coverage among children 5-11 years was 24% during the first two months of vaccine rollout, which was lower than coverage among those ages 12-15 years (33%) during the first two months of eligibility for that age group.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…3 Children might play an important role in the transmission of COVID-19, highlighting the importance of child vaccinations in the effort to reduce COVID-19 community transmission and hospitalization rates. 4 The U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children ages [5][6][7][8][9][10][11] years in the United States on October 29, 2021, which was endorsed on November 2, 2021, by the Centers for Disease Control and Prevention (CDC) based on recommendations from the Advisory Committee on Immunization Practices. 5 Administrative data reported to CDC showed that coverage among children 5-11 years was 24% during the first two months of vaccine rollout, which was lower than coverage among those ages 12-15 years (33%) during the first two months of eligibility for that age group.…”
Section: Introductionmentioning
confidence: 99%
“…8,9 The evaluation of disparities in receipt of routine childhood vaccinations is an important component of the national immunization program in the United States. 10 Understanding sociodemographic differences in COVID-19 vaccination and parental intent to vaccinate children ages 5-11 years during the first few months after the COVID-19 vaccine recommendation is essential in efforts to achieve higher vaccination coverage in this age group and addressing inequities in coverage early in the vaccination program. Better understanding of the associations between behavioral and social drivers of vaccine uptake and the willingness of parents to vaccinate their children might help to identify specific issues and demographic subgroups where tailored efforts might be helpful to improve vaccination coverage.…”
Section: Introductionmentioning
confidence: 99%
“…8 The initial Table also included a term called "residual seizure disorder." 5 A petitioner was considered to have suffered a residual seizure disorder if the petitioner did not suffer a seizure or convulsion unaccompanied by fever or accompanied by a fever of <102°F before the first seizure or convulsion after the administration of the vaccine involved and if (1) in the case of a measles, mumps, or rubella vaccine or any combination of such vaccines, the first seizure or convulsion occurred within 15 days after administration of the vaccine and two or more seizures or convulsions occurred within 1 year after the administration of the vaccine that were unaccompanied by fever or accompanied by a fever of <102°F; and (2) in the case of any other vaccine, the first seizure or convulsion occurred within 3 days after administration of the vaccine and two or more seizures or convulsions occurred within 1 year after the administration of the vaccine that were unaccompanied by fever or accompanied by a fever of <102°F.…”
Section: Key Pointsmentioning
confidence: 99%
“…The Program allows petitioners three distinct theories of recovery, thereby allowing causation to be proven by showing that (1) vaccine, (2) a preexisting condition was significantly aggravated by the vaccine, or (3) the vaccine was the causein-fact of the injury. If any of the various injuries in this Table occur within the statutorily defined time, a rebuttable presumption of causation has been proven.…”
Section: Key Pointsmentioning
confidence: 99%
See 1 more Smart Citation